Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia

Background and Aims: Cord blood leptin may reflect the leptinemic status of a newborn at birth more accurately than the leptin values of blood collected from other sites. The present study was undertaken to determine the relationship of cord serum leptin concentration at birth with neonatal and maternal anthropometric parameters. Materials and Methods: Blood was taken from the umbilical cord of the babies at delivery. Maternal anthropometric measurements were recorded at admission for delivery. Neonatal anthropometric measurements were recorded within 48 hours after delivery. Linear regression analysis was used to explore the relationship between cord serum leptin concentration and anthropometric parameters of the baby and the mother. Both Serum leptin and serum C-peptide levels were measured by chemiluminescence-based ELISA method. Results: The leptin concentration (ng/ml, mean±SD) in cord blood was 39.13±14.44. Cord leptin levels correlated with birth weight (r=0.673, p<0.0001), ponderal index (r=0.732, p<0.0001) but it did not correlate with maternal body mass index, gestational age (r=0.135, p=0.349) at delivery or cord serum C-peptide concentration (r=-0.049, p=0.735) or placental weight (r=0.203, p=0.157). Conclusion: There are associations between cord leptin concentration at delivery and birth weight, ponderal index (PI) of the babies but not body mass index (BMI) of the mothers. High leptin levels of the baby could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation. (J Bangladesh Coll Phys Surg 2007; 25 : 9-13)

Download Full-text

Anthropometric measurements and prevalence of obesity-related diseases: a cross-sectional study of overweight and obese patients in a novel multi-disciplinary weight management program

Obesity Abstracts ◽

10.1530/obabs.02.p6 ◽

2020 ◽

Author(s):

Mariam ElSaban ◽

Faisal Nawaz ◽

Mona Joumaa ◽

Amar Khamis ◽

Usama Warshow ◽

...

Keyword(s):

Weight Management ◽

Cross Sectional Study ◽

Management Program ◽

Anthropometric Measurements ◽

Obese Patients ◽

Weight Management Program ◽

Sectional Study ◽

Cross Sectional ◽

Prevalence Of Obesity

Download Full-text

Spinal cord compression due to extramedullary hematopoiesis in beta-thalassemia

Arquivos de Neuro-Psiquiatria ◽

10.1590/0004-282x20200075 ◽

2020 ◽

Vol 78 (10) ◽

pp. 663-664

Author(s):

Renan Ramon Souza LOPES ◽

Larissa Soares CARDOSO ◽

Franz ONISHI

Keyword(s):

Spinal Cord ◽

Spinal Cord Compression ◽

Extramedullary Hematopoiesis ◽

Cord Compression ◽

Beta Thalassemia

Download Full-text

ANTIGEN-SPECIFIC ANTIBODIES FIVE YEARS AFTER IMMUNISATION WITH A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ASPLENIC ADULTS WITH BETA-THALASSEMIA

10.26226/morressier.58fa1769d462b80290b51aeb ◽

2017 ◽

Author(s):

Ioanna Papadatou

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Beta Thalassemia ◽

Specific Antibodies

Download Full-text

Clinical-Reported Outcomes Of Deferoxamine Versus Deferasirox In The Treatment Of Homozygous BetaThalassemia

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v9ispl1.1382 ◽

2018 ◽

Vol 9 (SPL1) ◽

Author(s):

Zeina A Munim Al-Thanoon ◽

Mustafa Basil ◽

Nasih A Al-Kazzaz

Keyword(s):

Serum Ferritin ◽

Iron Chelation ◽

Iron Chelator ◽

Beta Thalassemia ◽

Control Group ◽

Current Standard ◽

Cross Sectional ◽

Significant Difference ◽

Multiple Blood ◽

Group 2

Iron chelation therapy with deferoxamine (DFO),the current standard for the treatment of iron overload in patients with betathalassemia,requires regular subcutaneous or intravenous infusions. This can lead to reduced quality of life and poor adherence,resulting in increased morbidity and mortality in iron-overloaded patients with beta-thalassemia. Deferasirox (DFX) is an orally administered iron chelator that has been approved for use in many countries. The requirement of an effective,well tolerated iron chelator with a less demanding mode of administration has led to the development of deferasirox. The present study was aimed to compare the satisfaction and compliance with deferoxamine versus deferasirox (Exjade®),a novel oral iron chelator in patients with transfusion - dependent beta- thalassemia. A cross-sectional,single-center investigation study was carried out in the Thalassemia Center of Ibn-Atheer Teaching Hospital in Nineveh province,Iraq. One hundred and eight thalassemic patients aged between 2- 20 years old having received multiple blood transfusions and a serum ferritin greater than 1500 ng/ml. Patients were randomised into two groups. Group 1 received deferoxamine at a dose of 20-50mg/kg/day and group 2 received deferasirox at the dose of 10-30 mg/kg/day. Another 56 apparently healthy volunteers were used as a control group. The assessment of chelation was done during the period between November 2013 and February 2014 by measurement of serum ferritin. Satisfaction and compliance was assessed by using a special questionnaire prepared by the researcher. Out of the 108 thalassemic patients enrolled there was no discontinuation in treatment with the two drugs under study. The serum ferritin did not change significantly in any of the chelation groups. In comparison with the patients who were treated with DFO,those receiving DFX reported a significantly higher rate of compliance and satisfaction (P < 0.05). However,no significant difference was observed between the two groups regarding their satisfaction (P > 0.05).Compliance with deferasirox (50 %) was more than that with deferoxamine (20 %). Satisfaction with deferoxamine was significantly lower than deferasirox (p= 0.00).

Download Full-text